Edition:
United States

Exalenz Bioscience Ltd (EXEN.TA)

EXEN.TA on Tel Aviv Stock Exchange

671.20ILa
22 Mar 2017
Change (% chg)

-- (--)
Prev Close
671.20
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
19,684
52-wk High
750.00
52-wk Low
201.35

Latest Key Developments (Source: Significant Developments)

Exalenz Bioscience Ltd says collaboration with Galectin Therapeutics
Monday, 3 Aug 2015 08:00am EDT 

Exalenz Bioscience Ltd:Says collaboration with Galectin Therapeutics.To use breathid to monitor patients with cirrhosis associated with nash.Says non-invasive breathid test to be used to follow treatment effect of gr-md-02 in phase II clinical study.Co to investigate clinical utility of breathid to follow up effect of treatment on patients with nash cirrhosis versus standard medical tests.  Full Article

More From Around the Web

BRIEF-Exalenz Bioscience receives fda marketing clearance for its laboratory system in the U.S.

* Exalenz Bioscience receives FDA marketing clearance for its laboratory system in the United States

No consensus analysis data available.